FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy
On Feb. 12, 2025, Genentech announced that the U.S. Food and Drug Administration (FDA) has approved a New…
FDA approved oral treatment for spinal muscular atrophy
On Aug. 7, 2020, the U.S. Food and Drug Administration (FDA) approved Genentech’s Evrysdi (risdiplam) to treat patients…